Biosig Technologies, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Streamex Corp. reports Q1 2026 financial results, highlighting the successful repayment of convertible debt and the expansion of its digital asset infrastructure.
Streamex Corp. reported a significantly wider net loss in Q3 2025, driven by its strategic acquisition of Streamex Exchange and a pivot towards digital commodity trading and blockchain technology.
BioSig Technologies reports a significant increase in net loss and working capital deficit for Q2 2025, driven by the Streamex acquisition and related expenses, while securing substantial new financing.
BioSig Technologies reports a net loss for Q1 2025 but regains compliance with Nasdaq listing requirements.
BioSig Technologies reports its Q3 2024 results, highlighting a significant reduction in operating expenses, a gain from debt settlement, and the reinstatement of its Nasdaq listing, while also noting ongoing financial challenges and internal control weaknesses.
BioSig Technologies reports a net loss of $7.455 million for the six months ended June 30, 2024, while navigating delisting from Nasdaq and significant operational changes.
BioSig Technologies faced significant challenges in Q1 2024, including workforce reductions, executive resignations, and a Nasdaq delisting notice, while reporting a net loss of $3.537 million.